Moderna (MRNA) Expected to Announce Earnings on Thursday

Moderna (NASDAQ:MRNA) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($2.90) per share and revenue of $130.35 million for the quarter.

Moderna Trading Up 1.3 %

NASDAQ:MRNA opened at $27.82 on Wednesday. The stock’s 50-day moving average is $29.91 and its 200-day moving average is $38.08. The stock has a market cap of $10.76 billion, a P/E ratio of -3.00 and a beta of 2.23. Moderna has a 1-year low of $23.15 and a 1-year high of $170.47.

Analysts Set New Price Targets

MRNA has been the subject of several research analyst reports. Morgan Stanley lowered their price objective on Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 9th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Thursday, April 17th. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $111.00 to $45.00 in a research note on Tuesday, February 18th. JPMorgan Chase & Co. reduced their price objective on Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Friday, March 21st. Finally, Berenberg Bank boosted their price target on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Moderna currently has a consensus rating of “Hold” and a consensus price target of $58.70.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.